Mural Oncology Q1 2024 net loss $30.9M, cash runway into Q4 2025 reaffirmed

Mural Oncology plc

2024-Q1 EPS reported -$1.84

Net loss $30.9M improved from $46.5M Q1 2023; R&D spend $26.9M down 33% YoY.
Cash, equivalents & marketable securities $231.7M as of March 31, 2024.
Nemvaleukin alfa registrational trials on track; ARTISTRY-7 interim OS data Q1 2025.
Less-frequent IV dosing trial for cutaneous melanoma enrolling; preliminary data H1 2025.
IL-18/IL-12 preclinical data presented at AACR; candidate nominations expected by end 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

Mural Oncology plc reported first quarter of 2024 results: net income Net loss was $30.9 million. Guidance reaffirmed.

Period: first quarter of 2024
Net income: Net loss was $30.9 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Mural Oncology plc (the "Company") issued a press release announcing the Company’s financial results for the three months ended March 31, 2024.

View on SEC.gov

Browse all earnings releases →

Source: SEC EDGAR

accession 0000950170-24-059071

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.